Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

Citations Over TimeTop 10% of 2008 papers

Abstract

Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N(4)-(2,3-dimethyl-2H-indazol-6-yl)-N(4)-methyl-N(2)-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

Related Papers

• → Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings(2016)19 cited
• → Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma(2012)
• The Effect of VEGF (Vascular endothelial growth factor) on Endothelial Cells in Pathogenesis of Preeclampsia(2002)
• → Περιεγχειρητική διακύμανση του αυξητικού παράγοντα αγγειακού ενδοθηλίου (vascular endothelial growth factor/VEGF) σε ασθενείς με καρκίνο παχέος εντέρου και ασθενείς με καρκίνο μαστού(2013)